Kyntra Bio appoints Andrew Singer to board, Maykin Ho resigns; CEO Wettig signs new severance agreement

KYNTRA BIO, INC.

Andrew E. Singer, MBA was appointed as a Class III director and Audit Committee member effective October 1, 2026; his term expires in 2029.
Maykin Ho, Ph.D. resigned from the board effective September 30, 2026 after serving since December 2018, including on the Audit Committee; no disagreement cited.
CEO Thane Wettig entered a new Change in Control and Severance Agreement on September 30, 2026, with a three-year term ending October 2, 2029; no material changes to pay.
Singer has 25+ years in biotech finance, led West Coast biotech investment banking at Credit Suisse, was Epizyme CFO, and advised on over $50 billion in transactions.
Kyntra Bio common stock trades on Nasdaq under KYNB; it focuses on oncology and rare disease therapies.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.